PETALING JAYA: Duopharma Biotech Bhd’s recent win for the supply of Insugen will contribute positively to the group’s earnings over the next three years. Assuming a profit after tax margin of 5%, the contract is estimated to contribute about RM6. 25mil( previously about RM4mil) per annum in net earnings.TA Securities Research reduced the company’s financial year 2021( FY21) earnings estimates by 2.4% after making some minor changes to its earnings model. However, it increased FY22-FY23 earnings
综合
星报-商业
2021-12-21 00:00:00.0